Loading...
Several cytotoxic regimens are often employed in the management of patients with advanced cervical cancer. Regrettably, advanced cervical cancer does not have a sustained response to chemotherapy. Bevacizumab has single-agent activity in heavily pretreated, recurrent cervical carcinoma (J Clin Oncol 2009; 27:1069).
Now, investigators have used a 2×2 factorial design to evaluate the effectiveness of bevacizumab in conjunction with either a nonplatinum doublet (topotecan and paclitaxel) or a platinum doublet (cisplatin and paclitaxel) in 452 patients with metastatic, recurrent, or persistent cervical cancer. Most patients had recurrent disease (72%) and had previously received platinum-based chemoradiotherapy (>70%).
At a median follow-up of 20…